TY - JOUR
T1 - Potential epigenetic therapeutics for atherosclerosis treatment
AU - Nicorescu, Ioana
AU - Dallinga, Geesje M.
AU - de Winther, Menno P. J.
AU - Stroes, Erik S. G.
AU - Bahjat, Mahnoush
PY - 2019
Y1 - 2019
N2 - Notwithstanding the intense efforts into the understanding and prevention of cardiovascular disease (CVD), its complex pathology remains the leading cause of mortality worldwide. The pivotal role of epigenetic changes in the control of gene expression has been profiled in several diseases, such as cancer and inflammatory disorders. In the last decade, increasing evidence has also linked aberrant epigenetic modulation as a contributor to CVD development. Differential profiles of DNA methylation, histone methylation and acetylation have consistently been observed in tissues and cells (comprising the aortic lesions, vascular endothelium and monocytes) from patients with CVD. This highlights the therapeutic potential of epigenetic drugs for cardiovascular treatment.
AB - Notwithstanding the intense efforts into the understanding and prevention of cardiovascular disease (CVD), its complex pathology remains the leading cause of mortality worldwide. The pivotal role of epigenetic changes in the control of gene expression has been profiled in several diseases, such as cancer and inflammatory disorders. In the last decade, increasing evidence has also linked aberrant epigenetic modulation as a contributor to CVD development. Differential profiles of DNA methylation, histone methylation and acetylation have consistently been observed in tissues and cells (comprising the aortic lesions, vascular endothelium and monocytes) from patients with CVD. This highlights the therapeutic potential of epigenetic drugs for cardiovascular treatment.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85054873256&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/30340764
U2 - https://doi.org/10.1016/j.atherosclerosis.2018.10.006
DO - https://doi.org/10.1016/j.atherosclerosis.2018.10.006
M3 - Article
C2 - 30340764
SN - 0021-9150
VL - 281
SP - 189
EP - 197
JO - Atherosclerosis
JF - Atherosclerosis
ER -